Acrivon Therapeutics Statistics
Total Valuation
ACRV has a market cap or net worth of $172.50 million. The enterprise value is -$10.94 million.
Important Dates
The next estimated earnings date is Thursday, March 27, 2025, before market open.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRV has 31.14 million shares outstanding. The number of shares has increased by 54.55% in one year.
| Current Share Class | 31.14M |
| Shares Outstanding | 31.14M |
| Shares Change (YoY) | +54.55% |
| Shares Change (QoQ) | +5.46% |
| Owned by Insiders (%) | 7.47% |
| Owned by Institutions (%) | 29.25% |
| Float | 11.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.88 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.75, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.75 |
| Quick Ratio | 12.65 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.95% and return on invested capital (ROIC) is -31.04%.
| Return on Equity (ROE) | -45.95% |
| Return on Assets (ROA) | -29.15% |
| Return on Invested Capital (ROIC) | -31.04% |
| Return on Capital Employed (ROCE) | -42.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.26M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.34% in the last 52 weeks. The beta is 0.78, so ACRV's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | +47.34% |
| 50-Day Moving Average | 6.01 |
| 200-Day Moving Average | 7.26 |
| Relative Strength Index (RSI) | 47.60 |
| Average Volume (20 Days) | 69,251 |
Short Selling Information
The latest short interest is 1.10 million, so 3.53% of the outstanding shares have been sold short.
| Short Interest | 1.10M |
| Short Previous Month | 1.17M |
| Short % of Shares Out | 3.53% |
| Short % of Float | 9.91% |
| Short Ratio (days to cover) | 29.98 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -85.30M |
| Pretax Income | -64.12M |
| Net Income | -76.98M |
| EBITDA | -84.45M |
| EBIT | -85.30M |
| Earnings Per Share (EPS) | -$2.58 |
Full Income StatementBalance Sheet
The company has $187.45 million in cash and $4.01 million in debt, giving a net cash position of $183.44 million or $5.89 per share.
| Cash & Cash Equivalents | 187.45M |
| Total Debt | 4.01M |
| Net Cash | 183.44M |
| Net Cash Per Share | $5.89 |
| Equity (Book Value) | 196.89M |
| Book Value Per Share | 6.32 |
| Working Capital | 174.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$60.68 million and capital expenditures -$3.09 million, giving a free cash flow of -$63.77 million.
| Operating Cash Flow | -60.68M |
| Capital Expenditures | -3.09M |
| Free Cash Flow | -63.77M |
| FCF Per Share | -$2.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |